Biomea Fusion, Inc. - SIC # 2834 - PHARMACEUTICAL PREPARATIONS

Ticker Exchange SIC # Website Latest Ticker
BMEA Nasdaq 2834 biomeafusion.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Biomea Fusion, Inc.

Biomea Fusion Presents New Clinical and Translational Data for Icovamenib at the American Diabetes Association (“ADA”) 86th Scientific Sessions and Announces Expansion of Ongoing Phase I BMF-650 Study - Jun 5th, 2026 5:32 pm
Biomea Fusion Announces Research Collaboration with University of Leicester to Evaluate Icovamenib in Combination with Semaglutide in Obesity - Jun 3rd, 2026 6:00 am
Biomea Fusion to Participate at Upcoming Investor Conferences - May 12th, 2026 2:05 pm
Biomea Fusion Reports First Quarter 2026 Financial Results and Corporate Highlights - May 11th, 2026 2:54 pm
Biomea Fusion Announces Poster Presentations of Icovamenib at the American Diabetes Association (ADA) 86th Scientific Sessions - May 5th, 2026 3:50 pm
Biomea Fusion Status Update: Experts Discuss Icovamenib’s Promise Ahead of ADA 2026 - May 5th, 2026 2:20 pm
Biomea Fusion Shares Early Type 1 Diabetes Data as COVALENT-112 Shows C-Peptide Gains with Icovamenib - Apr 28th, 2026 2:31 pm
Biomea Fusion Announces Positive 52-Week Results from Phase 2 COVALENT-112 Trial in Type 1 Diabetes Showing C-Peptide Improvement and Durability Following 12-Weeks of Icovamenib Treatment - Apr 27th, 2026 3:37 pm
Biomea Fusion Announces First Patient Dosed in Newly Initiated Phase II Programs Enrolling Type 2 Diabetes Patients Failing on Standard-of-Care Therapies - Mar 31st, 2026 5:00 am
Biomea Fusion Details Icovamenib Diabetes Milestones, Teases BMF-650 Obesity Readouts - Mar 30th, 2026 3:03 pm
Biomea Fusion Teases Q2 Phase 1 Data for Oral GLP-1 BMF-650, Advances Icovamenib in Diabetes - Mar 30th, 2026 12:24 pm
Can Biomea Fusion (NASDAQ:BMEA) Afford To Invest In Growth? - Mar 27th, 2026 4:26 am
Analysts Sentiment on Biomea Fusion (BMEA) Remains Strong Amid Strong Diabetes Trial Results - Mar 25th, 2026 1:32 pm
Biomea Fusion Reports Full Year 2025 Financial Results and Corporate Highlights - Mar 24th, 2026 2:05 pm
Biomea Fusion Presents Phase II COVALENT-111 Data in Type 2 Diabetes at the 19th International Conference on Advanced Technologies & Treatments for Diabetes 2026 - Mar 14th, 2026 2:30 am
Biomea Fusion Details Diabetes, Obesity Pipeline at Citizens Conference, Sees Cash Runway to Q1 2027 - Mar 13th, 2026 1:28 am
Biomea Fusion Spotlights Durable Diabetes Data, Oral GLP-1 Weight-Loss Program at Oppenheimer Conf. - Feb 26th, 2026 9:14 pm
Biomea Fusion, Inc.'s (NASDAQ:BMEA) largest shareholders are retail investors with 55% ownership, institutions own 38% - Jan 24th, 2026 6:09 am
Rodman & Renshaw Initiates Biomea Fusion (BMEA) at Buy with $8 Price Target - Jan 19th, 2026 6:01 am
Biomea Fusion Spotlights Diabetes, Obesity Pipeline at JPMorgan Conference, Sets 2026 Milestones - Jan 15th, 2026 6:48 am